See more : Absolute Clean Energy Public Company Limited (ACE.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Schrödinger, Inc. (SDGR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Schrödinger, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Black Tusk Resources Inc. (BTKRF) Income Statement Analysis – Financial Results
- Rubicon Organics Inc. (ROMJ.V) Income Statement Analysis – Financial Results
- Candela Invest SA (CAND.BR) Income Statement Analysis – Financial Results
- Carasso Motors Ltd. (CRSO.TA) Income Statement Analysis – Financial Results
- Highwater Ethanol, LLC (HEOL) Income Statement Analysis – Financial Results
Schrödinger, Inc. (SDGR)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.schrodinger.com
About Schrödinger, Inc.
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 216.67M | 180.96M | 137.93M | 108.10M | 85.54M | 66.64M | 55.69M |
| Cost of Revenue | 75.97M | 79.93M | 72.31M | 44.62M | 36.45M | 23.70M | 15.89M |
| Gross Profit | 140.69M | 101.02M | 65.62M | 63.47M | 49.09M | 42.94M | 39.80M |
| Gross Profit Ratio | 64.93% | 55.83% | 47.57% | 58.72% | 57.39% | 64.43% | 71.46% |
| Research & Development | 181.77M | 126.37M | 90.90M | 64.70M | 39.40M | 34.52M | 27.67M |
| General & Administrative | 99.15M | 90.83M | 64.01M | 41.90M | 27.04M | 18.55M | 14.44M |
| Selling & Marketing | 37.23M | 30.64M | 22.15M | 17.80M | 21.36M | 17.83M | 16.72M |
| SG&A | 136.37M | 121.47M | 86.16M | 59.69M | 48.40M | 36.38M | 31.15M |
| Other Expenses | 0.00 | 3.95M | 1.06M | 2.25M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 318.14M | 247.84M | 177.06M | 124.39M | 87.81M | 70.91M | 58.82M |
| Cost & Expenses | 394.11M | 327.77M | 249.37M | 169.01M | 124.26M | 94.61M | 74.71M |
| Interest Income | 0.00 | 3.95M | 1.06M | 2.25M | 1.88M | 433.00K | 359.00K |
| Interest Expense | 0.00 | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.55M | 4.34M | 2.85M | 3.66M | 3.64M | 2.89M | 1.69M |
| EBITDA | -171.90M | -142.47M | -108.60M | -57.26M | -35.08M | -25.08M | -17.34M |
| EBITDA Ratio | -79.34% | -80.01% | -86.97% | -79.12% | -52.60% | -36.41% | -28.18% |
| Operating Income | -177.45M | -149.12M | -111.44M | -60.92M | -38.72M | -27.97M | -19.02M |
| Operating Income Ratio | -81.90% | -82.41% | -80.80% | -56.35% | -45.26% | -41.97% | -34.15% |
| Total Other Income/Expenses | 220.37M | -2.31M | 10.64M | 34.62M | 12.74M | -379.00K | 1.96M |
| Income Before Tax | 42.92M | -149.13M | -100.81M | -26.29M | -25.97M | -28.35M | -17.06M |
| Income Before Tax Ratio | 19.81% | -82.41% | -73.09% | -24.32% | -30.36% | -42.54% | -30.63% |
| Income Tax Expense | 2.20M | 63.00K | 411.00K | 345.00K | -291.00K | 77.00K | 332.00K |
| Net Income | 40.72M | -149.19M | -101.22M | -26.64M | -25.68M | -28.43M | -17.39M |
| Net Income Ratio | 18.79% | -82.45% | -73.38% | -24.64% | -30.02% | -42.66% | -31.23% |
| EPS | 0.57 | -2.10 | -1.43 | -0.44 | -0.41 | -0.59 | -0.43 |
| EPS Diluted | 0.54 | -2.10 | -1.43 | -0.44 | -0.41 | -0.59 | -0.43 |
| Weighted Avg Shares Out | 71.78M | 71.17M | 70.59M | 60.02M | 63.27M | 48.47M | 40.38M |
| Weighted Avg Shares Out (Dil) | 74.99M | 71.17M | 70.59M | 60.02M | 63.27M | 48.47M | 40.38M |
3 Artificial Intelligence Stocks That Could Outperform the ‘Godfather of AI'
7 Trailblazing AI Stocks to Buy on Any Weakness
Schrodinger: Leading The AI Healthcare Revolution
This AI Biotech Stock Is Already Profitable. Should You Buy It?
The Good And Bad: Allison Transmission & Schrodinger Inc.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3 AI Drug Discovery Stocks to Watch
Schrodinger: More Than An AI Bubble Stock
7 Stocks the Big Money Is Buying Now
Biotech Breakthroughs: 3 Companies on the Cusp of Major Discoveries
Source: https://incomestatements.info
Category: Stock Reports